World Investment Advisors Purchases 379 Shares of Vertex Pharmaceuticals Incorporated $VRTX

World Investment Advisors grew its position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 43.4% in the second quarter, according to its most recent filing with the SEC. The fund owned 1,253 shares of the pharmaceutical company’s stock after acquiring an additional 379 shares during the period. World Investment Advisors’ holdings in Vertex Pharmaceuticals were worth $558,000 as of its most recent filing with the SEC.

A number of other large investors also recently modified their holdings of VRTX. Activest Wealth Management bought a new position in shares of Vertex Pharmaceuticals in the 1st quarter valued at $25,000. Clal Insurance Enterprises Holdings Ltd lifted its stake in shares of Vertex Pharmaceuticals by 450.0% in the 1st quarter. Clal Insurance Enterprises Holdings Ltd now owns 55 shares of the pharmaceutical company’s stock valued at $27,000 after acquiring an additional 45 shares during the last quarter. Flaharty Asset Management LLC bought a new position in shares of Vertex Pharmaceuticals in the 1st quarter valued at $32,000. American National Bank & Trust lifted its stake in shares of Vertex Pharmaceuticals by 515.4% in the 2nd quarter. American National Bank & Trust now owns 80 shares of the pharmaceutical company’s stock valued at $36,000 after acquiring an additional 67 shares during the last quarter. Finally, Solstein Capital LLC bought a new position in shares of Vertex Pharmaceuticals in the 2nd quarter valued at $40,000. 90.96% of the stock is currently owned by institutional investors.

Vertex Pharmaceuticals Trading Up 1.4%

Shares of Vertex Pharmaceuticals stock opened at $425.57 on Monday. The business has a 50-day moving average price of $401.71 and a two-hundred day moving average price of $431.57. Vertex Pharmaceuticals Incorporated has a 1-year low of $362.50 and a 1-year high of $519.88. The company has a market cap of $109.11 billion, a P/E ratio of 30.42 and a beta of 0.43.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its quarterly earnings results on Monday, August 4th. The pharmaceutical company reported $4.52 earnings per share for the quarter, topping analysts’ consensus estimates of $4.24 by $0.28. Vertex Pharmaceuticals had a return on equity of 23.91% and a net margin of 31.86%.The firm had revenue of $2.94 billion during the quarter, compared to the consensus estimate of $2.90 billion. During the same period last year, the business posted ($12.83) EPS. The business’s revenue was up 11.3% compared to the same quarter last year. Equities research analysts forecast that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current fiscal year.

Insiders Place Their Bets

In other Vertex Pharmaceuticals news, Director Bruce I. Sachs purchased 5,000 shares of the firm’s stock in a transaction on Wednesday, August 6th. The stock was purchased at an average cost of $389.68 per share, for a total transaction of $1,948,400.00. Following the acquisition, the director owned 45,000 shares in the company, valued at approximately $17,535,600. The trade was a 12.50% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 0.20% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently commented on VRTX. Weiss Ratings reiterated a “hold (c+)” rating on shares of Vertex Pharmaceuticals in a research note on Wednesday, October 8th. Guggenheim decreased their price objective on Vertex Pharmaceuticals from $558.00 to $546.00 and set a “buy” rating for the company in a report on Wednesday, August 6th. Truist Financial set a $490.00 price objective on Vertex Pharmaceuticals and gave the company a “buy” rating in a report on Tuesday, August 5th. Leerink Partnrs upgraded Vertex Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Thursday, September 25th. Finally, BMO Capital Markets set a $530.00 price objective on Vertex Pharmaceuticals and gave the company an “outperform” rating in a report on Tuesday, August 5th. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and twelve have given a Hold rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $492.10.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.